DE69730038D1 - Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen - Google Patents

Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen

Info

Publication number
DE69730038D1
DE69730038D1 DE69730038T DE69730038T DE69730038D1 DE 69730038 D1 DE69730038 D1 DE 69730038D1 DE 69730038 T DE69730038 T DE 69730038T DE 69730038 T DE69730038 T DE 69730038T DE 69730038 D1 DE69730038 D1 DE 69730038D1
Authority
DE
Germany
Prior art keywords
fusion proteins
multivalents
monovalents
soluble
mhc class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69730038T
Other languages
English (en)
Other versions
DE69730038T2 (de
Inventor
W Wucherpfennig
L Strominger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of DE69730038D1 publication Critical patent/DE69730038D1/de
Application granted granted Critical
Publication of DE69730038T2 publication Critical patent/DE69730038T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69730038T 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen Expired - Fee Related DE69730038T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2407796P 1996-08-16 1996-08-16
US24077P 1996-08-16
PCT/US1997/014503 WO1998006749A2 (en) 1996-08-16 1997-08-15 Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor

Publications (2)

Publication Number Publication Date
DE69730038D1 true DE69730038D1 (de) 2004-09-02
DE69730038T2 DE69730038T2 (de) 2004-11-25

Family

ID=21818743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730038T Expired - Fee Related DE69730038T2 (de) 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen

Country Status (11)

Country Link
EP (1) EP0935607B1 (de)
JP (1) JP2000516470A (de)
AT (1) ATE272070T1 (de)
AU (1) AU730457B2 (de)
CA (1) CA2263195A1 (de)
DE (1) DE69730038T2 (de)
DK (1) DK0935607T3 (de)
ES (1) ES2221065T3 (de)
NZ (1) NZ333915A (de)
PT (1) PT935607E (de)
WO (1) WO1998006749A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0889964A1 (de) 1996-03-28 1999-01-13 The Johns Hopkins University Lösliche divalente und multivalente heterodimäre proteinanalogen
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
CA2321262A1 (en) * 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
JP2002515244A (ja) * 1998-05-19 2002-05-28 アヴィデックス リミテッド 可溶性ｔ細胞受容体
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
DE60138922D1 (de) 2000-10-10 2009-07-16 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
CA2438376A1 (en) * 2000-12-18 2002-08-15 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of antigens and uses thereof
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
EP1400534B1 (de) * 2002-09-10 2015-10-28 Affimed GmbH Menschlicher CD3-spezifischer Antikörper mit immunosupressiven Eigenschaften
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
EP1688432B1 (de) 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Stabilisierte lösung mit hoher igm-konzentration
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
EP2361930A3 (de) 2007-03-26 2011-10-26 Dako Denmark A/S Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten
EP2167536A1 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Mhc-multimere, verfahren zu ihrer herstellung, markierung und verwendung
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US20150044245A1 (en) * 2012-01-06 2015-02-12 Oregon Health & Science University Partial mhc constructs and methods of use
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
SG11201609917PA (en) 2014-05-29 2016-12-29 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP4270006A3 (de) 2014-06-13 2024-01-10 Immudex ApS Allgemeiner nachweis und isolierung spezifischer zellen durch binden markierter moleküle
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
JP7320944B2 (ja) 2015-10-08 2023-08-04 マクロジェニクス，インコーポレーテッド Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN110291111A (zh) * 2016-11-09 2019-09-27 优迪有限合伙公司 重组pMHC II类分子
WO2018197949A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US20220275043A1 (en) * 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
CN112816595A (zh) * 2021-01-06 2021-05-18 海默斯（重庆）医学生物技术有限公司 一种重组角蛋白液体制剂及其纯度检测方法
CA3215077A1 (en) * 2021-04-07 2022-10-13 Thomas J. Malia Peptide-mhc-immunoglobulin multimers and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
WO1996004314A1 (en) * 1994-07-29 1996-02-15 Dade International, Inc. Mhc complexes and uses thereof

Also Published As

Publication number Publication date
AU730457B2 (en) 2001-03-08
DK0935607T3 (da) 2004-12-06
WO1998006749A2 (en) 1998-02-19
AU4072397A (en) 1998-03-06
WO1998006749A3 (en) 1998-06-11
ES2221065T3 (es) 2004-12-16
NZ333915A (en) 2000-11-24
EP0935607A2 (de) 1999-08-18
PT935607E (pt) 2004-12-31
ATE272070T1 (de) 2004-08-15
JP2000516470A (ja) 2000-12-12
EP0935607B1 (de) 2004-07-28
CA2263195A1 (en) 1998-02-19
DE69730038T2 (de) 2004-11-25

Similar Documents

Publication Publication Date Title
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
ATE96840T1 (de) Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
CA2045869A1 (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
UA26855C2 (uk) Фармацевтичhа композиція, яка регулює гематопоез
ATE328068T1 (de) Papillomavirus vakzine
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
DK0538300T3 (da) O-Glycosyleret IFN-alfa
MY102472A (en) Preparation of funtional human urokinase proteins.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
BG102362A (en) New derivatives of amino acids, their preparation and application
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DE69315341D1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
DE69012958D1 (de) Fibrinolytisches Protein und Herstellungsweise dafür.
EA199801032A1 (ru) Белки zona pellucida для контрацепции
UA26246C2 (uk) Коhтрацептивhий комбіhоваhий препарат

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee